Actelion announced that its PGI2 receptor agonist, ACT-293987, generated positive results in a Phase IIa study evaluating the drug candidate as a potential treatment for patients with pulmonary arterial hypertension (PAH).

[ad]

Based on the results, the company said it would advance the first-in-class compound into late-stage testing before the end of the year. The primary endpoint of the randomised, placebo-controlled study, which involved 43 patients, was change from baseline in pulmonary vascular resistance.

Vontobel analyst Andrew Weiss indicated that the drug “is a very interesting compound and could significantly expand the treatment options Actelion offers to PAH patients.” Weiss added that “a filing for (approval) is likely in 2013.” ACT-293987 is being developed in collaboration with Nippon Shinyaku.

Source: FirstWord

Popularity: 4% [?]